# An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

> **NCT01467505** · PHASE2 · TERMINATED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 61 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Telaprevir
- **DRUG:** Ribavirin
- **DRUG:** Pegylated Interferon Alfa-2a
- **DRUG:** Immunosuppressant Regimen

## Key facts

- **NCT ID:** NCT01467505
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify the drug development plan.
- **Last updated:** 2015-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01467505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01467505, "An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01467505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*